In addition, activation of the LKB1/AMPK pathway by metformin which is the first-line treatment for type 2 diabetes, suppresses IL-6-induced STAT3 expression and NF-κB activation in various cancers [141,142,143,144]. Here, STAT3 is linked to cancer.